S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:LSTA

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

$3.12
-0.14 (-4.29%)
(As of 03/28/2024 ET)
Today's Range
$3.10
$3.27
50-Day Range
$2.47
$3.35
52-Week Range
$1.95
$4.53
Volume
14,230 shs
Average Volume
21,020 shs
Market Capitalization
$25.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Lisata Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
380.8% Upside
$15.00 Price Target
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Lisata Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.08) to ($2.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

420th out of 939 stocks

Pharmaceutical Preparations Industry

201st out of 444 stocks

LSTA stock logo

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

LSTA Stock Price History

LSTA Stock News Headlines

Lisata Therapeutics (NASDAQ:LSTA) Trading Up 1.8%
Lisata Therapeutics (NASDAQ:LSTA) Trading 1.8% Higher
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Q4 2023 Lisata Therapeutics Inc Earnings Call
Recap: Lisata Therapeutics Q4 Earnings
Lisata Therapeutics's Earnings Outlook
Lisata Therapeutics Inc LSTA
See More Headlines
Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LSTA
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+380.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.88 per share

Miscellaneous

Free Float
6,513,000
Market Cap
$25.93 million
Optionable
Not Optionable
Beta
1.03
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. David J. Mazzo B.A. (Hons) (Age 67)
    B.Sc. (Hons.), M.Sc., Ph.D., President, CEO & Director
    Comp: $1.16M
  • Dr. Kristen K. Buck M.D. (Age 49)
    Executive VP of R&D and Chief Medical Officer
    Comp: $938.42k
  • Mr. James Nisco
    VP of Finance & Treasury
  • Mr. Tariq Imam
    Vice President of Business Development & Operations and Corporate Counsel
  • Mr. Gregory S. Berkin
    Chief Information Officer
  • Mr. John D. Menditto
    Vice President of Investor Relations & Corporate Communications
  • Ms. Gail Holler (Age 65)
    Vice President of Human Resources
  • Dr. William K. Sietsema Ph.D. (Age 68)
    Vice President of Global Regulatory Affairs
    Comp: $350.55k

LSTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lisata Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LSTA shares.
View LSTA analyst ratings
or view top-rated stocks.

What is Lisata Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 1-year price objectives for Lisata Therapeutics' shares. Their LSTA share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 380.8% from the stock's current price.
View analysts price targets for LSTA
or view top-rated stocks among Wall Street analysts.

How have LSTA shares performed in 2024?

Lisata Therapeutics' stock was trading at $2.73 at the start of the year. Since then, LSTA stock has increased by 14.3% and is now trading at $3.12.
View the best growth stocks for 2024 here
.

Are investors shorting Lisata Therapeutics?

Lisata Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 9,900 shares, an increase of 28.6% from the February 29th total of 7,700 shares. Based on an average daily volume of 14,400 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.2% of the shares of the stock are short sold.
View Lisata Therapeutics' Short Interest
.

When is Lisata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LSTA earnings forecast
.

How were Lisata Therapeutics' earnings last quarter?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.20.

Who are Lisata Therapeutics' major shareholders?

Lisata Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (3.31%), Citadel Advisors LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LSTA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners